Shares of Vallon Pharmaceuticals Inc. fell 77.5% in premarket trading on Monday after the company said its experimental formulation of an abuse-deterrent attention deficit hyperactivity disorder drug did not meet the primary endpoint in a clinical trial. The company said it plans to do more research assessing the formulation using different endpoints. Vallon’s stock has gained 24.4% so far this year, while the broader S&P 500 is down 6.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
